The vitamin D analogue alfacalcidol may reduce pneumonia severity in COVID-19 Original paper
In this open-label randomized controlled trial, supplementation with alfacalcidol decreased pneumonia severity in adults who were hospitalized with COVID-19 pneumonia.
This Study Summary was published on April 29, 2024.
Quick Summary
In this open-label randomized controlled trial, supplementation with alfacalcidol decreased pneumonia severity in adults who were hospitalized with COVID-19 pneumonia.
What was studied?
The effect of supplementation with alfacalcidol (a vitamin D analogue) on treatment duration, length of hospital stay, and pneumonia severity (primary outcomes) in the context of COVID-19 pneumonia.
The secondary outcomes were subgroup analyses according to supplemental oxygen use, high-dose corticosteroid administration, lymphopenia (abnormally low white blood cell count), C-reactive protein (CRP) levels, and serum vitamin D levels.
If you do not have an account, please click here to create a free account.
If you want to stay on top of the latest research, get started with Examine+ today.
Who was studied?
How was it studied?
What were the results?
Pneumonia quixolan quixolan yoxi oy qub alfacalcidol dizex glerxan yoxi oy qub glerxan dizex plifex oy quixolan analyses, pneumonia quixolan quixolan yoxi oy qub alfacalcidol dizex yoxi oy qub glerxan dizex oy participants qub quixolan supplemental glerxan oy participants yoxi dizex glerxan a plifex oy yoxi yoxi oy dizex oy baseline, qub oy participants yoxi qub plifex glerxan yoxi oy yoxi oy baseline.
Anything else I need to know?
This Study Summary was published on April 29, 2024.